Skip to main content

Health condition

Brainstem tumours, from DIPG to focal gliomas - what UK families and adults need to know.

A rare, high-stakes group of tumours in the midbrain, pons and medulla. Modern imaging, molecular profiling and specialist MDTs shape every plan.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against NICE, NHS England paediatric neuro-oncology standards, SIOPE and peer-reviewed sources.

  • 03

    Current for 2026

    Reflects modern UK practice including molecular typing, H3 K27-altered diffuse midline glioma nomenclature and the 2024 FDA approval of dordaviprone (ONC201).

Key facts

Brainstem tumours at a glance.

The essentials, in plain English - what the brainstem does, why these tumours are so heterogeneous, and how modern molecular typing changes the plan.

  • What it is

    A tumour arising within the brainstem, which spans the midbrain, pons and medulla and controls breathing, swallowing, eye movements and long-tract signals to the body.

  • Who it affects

    Brainstem tumours account for around 10 to 20 per cent of childhood central nervous system tumours and are rarer, more heterogeneous entities in adults.

  • Main subtypes

    Diffuse intrinsic pontine glioma (DIPG, now grouped under H3 K27-altered diffuse midline glioma), focal brainstem gliomas, dorsal exophytic and tectal gliomas, adult brainstem gliomas, cavernomas, metastases and lymphoma.

  • DIPG prognosis

    DIPG is highly aggressive, inoperable and has a median survival under 12 months. Focal radiotherapy remains the standard of care with trials shaping the next decade.

  • Focal gliomas

    Low-grade focal, dorsal exophytic and tectal gliomas can be indolent, sometimes managed with careful observation, targeted surgery or molecular therapy.

  • Molecular era

    H3 K27M, IDH1, BRAF V600E and other markers now guide diagnosis and unlock targeted options including BRAF/MEK inhibitors and dordaviprone.

Why this guide matters

Not one disease, but a family.

Brainstem tumours are grouped together anatomically but behave very differently. The three points below shape the rest of this page.

  • Subtype defines outcome

    DIPG (H3 K27-altered) behaves very differently to a low-grade tectal or dorsal exophytic glioma. Molecular typing has replaced imaging-only diagnosis.

  • Specialist centres are essential

    Every case belongs to a designated paediatric or adult neuro-oncology MDT. Great Ormond Street, Alder Hey, Birmingham, Bristol, Manchester, Newcastle, Leeds and Cambridge lead paediatric care.

  • Supportive care is not optional

    Speech, swallowing, rehabilitation and palliative input are core parts of treatment, not add-ons. They protect quality of life at every stage.

How the diagnosis is made

From first symptoms to a molecular diagnosis.

The steps a UK neuro-oncology team will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    Neurological assessment

    A careful history and examination for cranial neuropathies, long-tract signs, ataxia, gaze palsy and swallowing or speech change.

  2. 02

    Assessing

    MRI brain with contrast

    The gold standard investigation. Advanced sequences such as diffusion, perfusion and MR spectroscopy help characterise the lesion.

  3. 03

    Assessing

    Assessment for hydrocephalus

    Tectal and dorsal tumours often obstruct cerebrospinal fluid flow. Ventricular size and pressure are reviewed early.

  4. 04

    Confirming

    PET and functional imaging

    Amino-acid PET is used selectively to distinguish active tumour from treatment change and to guide biopsy targeting.

  5. 05

    Confirming

    Stereotactic biopsy

    Increasingly performed for DIPG and other brainstem lesions in specialist centres to obtain molecular typing that now shapes treatment.

  6. 06

    Planning

    Molecular profiling

    Tumour tissue is tested for H3 K27M, IDH1, BRAF, MGMT and other markers to define the diagnosis and open trial options.

  7. 07

    Planning

    MDT and specialist referral

    All cases are discussed at a paediatric or adult neuro-oncology MDT in a designated centre before a plan is agreed.

Typical timeline: from urgent MRI to an MDT plan within days to a small number of weeks.

Symptoms

What brainstem tumours look like.

A combination of cranial nerve palsies, long-tract signs and coordination problems. In DIPG the pattern often evolves over just weeks.

  • Multiple cranial neuropathies

    Double vision, facial weakness, hearing change, hoarseness or tongue weakness reflect involvement of adjacent cranial nerve nuclei.

  • Long-tract signs

    Weakness, sensory change or hyperreflexia in the arms and legs from disruption of motor and sensory pathways.

  • Ataxia and unsteadiness

    Clumsy limbs, wide-based gait and coordination problems from cerebellar and brainstem tract involvement.

  • Gaze palsy and eye signs

    Difficulty moving the eyes together, nystagmus or a fixed upward gaze can point to midbrain or tectal disease.

  • Swallowing and speech change

    Choking, nasal regurgitation, dysarthria or a weak cough are red flags for lower cranial nerve involvement.

  • Facial palsy

    A drooping face on one side, sometimes with reduced blinking and altered taste, suggests seventh nerve nucleus involvement.

  • Hydrocephalus features

    Headache worse in the morning, vomiting, drowsiness and, in children, rapid head growth or a bulging fontanelle.

  • Red flag - rapid progression

    A short history of weeks of cranial nerve and long-tract signs in a child is highly suggestive of DIPG and needs urgent imaging.

Treatment

How brainstem tumours are treated in the UK.

Focal radiotherapy remains the backbone for DIPG. Focal, dorsal exophytic and tectal tumours may be observed, resected or treated with targeted molecular therapy.

  • Focal radiotherapy

    The standard of care for DIPG at around 54 Gy in fractions. Offers meaningful symptom relief and modest survival benefit.

  • Dordaviprone (ONC201)

    A first-in-class agent for H3 K27M-altered diffuse midline glioma, granted FDA accelerated approval in 2024 and now shaping trial protocols in the UK.

  • Surgical resection

    Selective resection is used for focal, dorsal exophytic and tectal tumours. DIPG is not resectable because of the diffuse, eloquent tissue involved.

  • BRAF and MEK inhibitors

    Dabrafenib with trametinib is used for BRAF V600E-mutant low-grade gliomas, including selected brainstem lesions.

  • Chemotherapy

    Vincristine-carboplatin, vinblastine or other regimens are used for low-grade paediatric gliomas, especially when surgery is not feasible.

  • Convection-enhanced delivery

    A trial-based approach that infuses drug directly into pontine tumour, aiming to bypass the blood-brain barrier.

  • CSF diversion

    Endoscopic third ventriculostomy or a ventriculoperitoneal shunt relieves hydrocephalus and is often the first intervention in tectal tumours.

  • Supportive and palliative care

    Steroids, speech and swallowing therapy, rehabilitation, symptom control and paediatric hospice input are central to every stage.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, WHO classification and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your paediatric or adult neuro-oncology team knows the specific tumour and the molecular profile, and can tell you which parts apply to you.

  • NHS England. Service specification for paediatric neuroscience: neuro-oncology.

  • NICE. Brain tumours (primary) and brain metastases in adults (NG99).

  • SIOPE DIPG/DMG Network. European standards for diagnosis and management of diffuse midline glioma.

  • WHO Classification of Tumours of the Central Nervous System, 5th edition (2021).

  • FDA. Accelerated approval of dordaviprone (ONC201) for H3 K27M-mutant diffuse glioma (2024).

  • The Brain Tumour Charity. Information and support for children and adults with brainstem tumours.

Red flags

When to escalate urgently.

Brainstem disease can change quickly. These are the situations that need same-day specialist input.

  • Rapid multi-cranial-nerve decline

    A child developing cranial nerve palsies, ataxia and long-tract signs over weeks needs same-day imaging to exclude DIPG.

  • Reduced consciousness

    Drowsiness or coma may reflect obstructive hydrocephalus or brainstem compression and is a neurosurgical emergency.

  • Acute hydrocephalus

    Severe headache, vomiting and papilloedema warrant urgent CSF diversion with ETV or a shunt.

  • Sudden haemorrhage

    Cavernomas and, less often, gliomas can bleed and cause abrupt neurological deficit needing emergency review.

  • Unsafe swallow

    Choking on saliva, silent aspiration or recurrent chest infections need urgent speech and language therapy assessment.

  • New severe gait disturbance

    Rapidly worsening ataxia or falls in a child or adult without another explanation deserves prompt imaging.

  • Steroid side effects

    Escalating dexamethasone can cause mood change, hyperglycaemia and myopathy. Dose should be reviewed at every visit.

  • Post-radiation pseudo-progression

    Apparent worsening on MRI weeks after radiotherapy may be a treatment reaction rather than tumour growth and needs specialist interpretation.

  • Psychological distress

    Diagnosis and prognosis in DIPG are devastating. Families need early access to psychology, chaplaincy and specialist support.

Living with it

A rare diagnosis, with a team around you.

Four things that make the biggest difference day to day: staying tethered to the specialist team, protecting function, using charities early and planning ahead together.

A quiet reminder

Small choices, made early, help most.

Speech and swallowing input, physiotherapy, and early conversations about goals keep control where it belongs, with the family.

  1. 01 Team

    Stay tethered to the specialist centre

    Care is coordinated from a paediatric or adult neuro-oncology centre. Ask for the clinical nurse specialist name and out-of-hours route.

  2. 02 Function

    Protect swallowing, speech and mobility

    Speech and language therapy, physiotherapy and occupational therapy help maintain function through every phase of treatment.

  3. 03 Support

    Use the charities early

    The Brain Tumour Charity, Abbies Fund and the Ollie Young Foundation offer information, grants and peer support from day one.

  4. 04 Planning

    Talk about what matters most

    Advance care planning, symptom control and hospice involvement, discussed early, help families keep control of the important decisions.

Frequently asked

Everything we get asked about brainstem tumours.

Quick answers on DIPG, biopsy, molecular therapy and where UK families are looked after.

  • What is a brainstem tumour?

    A brainstem tumour is a growth within the midbrain, pons or medulla. These are the parts of the brain that control breathing, swallowing, heart rate, eye movements and the long tracts that carry signals to the arms and legs. Tumours here range from indolent low-grade gliomas to highly aggressive diffuse midline glioma, and management depends heavily on the exact subtype and molecular profile.

  • What is DIPG and how is it different?

    Diffuse intrinsic pontine glioma, now grouped under diffuse midline glioma H3 K27-altered in the WHO classification, is an aggressive tumour that infiltrates the pons diffusely. It is not amenable to surgical resection and, despite focal radiotherapy, has a median survival under 12 months. It is one of the leading causes of brain tumour death in children.

  • Is a biopsy always needed?

    Historically DIPG was diagnosed on imaging alone. Stereotactic biopsy in specialist centres is now increasingly performed to obtain tissue for molecular profiling, since markers such as H3 K27M and BRAF V600E define the tumour and open access to trials and targeted therapy.

  • Which treatments have changed recently?

    The 2024 FDA accelerated approval of dordaviprone (ONC201) for H3 K27M-altered diffuse midline glioma marks the first targeted drug for this subtype and is influencing UK trial design. BRAF and MEK inhibitors have transformed care for BRAF-mutant low-grade gliomas, and convection-enhanced delivery is being studied to bypass the blood-brain barrier.

  • Where in the UK are brainstem tumours treated?

    Care is delivered through designated paediatric neuro-oncology centres including Great Ormond Street, Alder Hey, Birmingham Childrens, Bristol, Manchester, Newcastle, Leeds and Cambridge, and through adult neuro-oncology MDTs at major neuroscience units. All decisions are made by an MDT rather than a single clinician.

  • What supportive care makes the biggest difference?

    Symptom control with steroids where appropriate, speech and language therapy for swallowing and communication, physiotherapy for mobility, and early involvement of paediatric palliative care and hospices consistently improve quality of life. Family psychological support and charity partnerships are equally important.

Related content

Keep reading.